HK1217958A1 - 四價雙特異性抗體 - Google Patents
四價雙特異性抗體Info
- Publication number
- HK1217958A1 HK1217958A1 HK16105955.4A HK16105955A HK1217958A1 HK 1217958 A1 HK1217958 A1 HK 1217958A1 HK 16105955 A HK16105955 A HK 16105955A HK 1217958 A1 HK1217958 A1 HK 1217958A1
- Authority
- HK
- Hong Kong
- Prior art keywords
- bispecific antibodies
- tetravalent bispecific
- tetravalent
- antibodies
- bispecific
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/46—Hybrid immunoglobulins
- C07K16/468—Immunoglobulins having two or more different antigen binding sites, e.g. multifunctional antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/283—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against Fc-receptors, e.g. CD16, CD32, CD64
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2887—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against CD20
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2893—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against CD52
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/32—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/35—Valency
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
- C07K2317/522—CH1 domain
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
- C07K2317/524—CH2 domain
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
- C07K2317/526—CH3 domain
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/55—Fab or Fab'
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/64—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising a combination of variable region and constant region components
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/66—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising a swap of domains, e.g. CH3-CH2, VH-CL or VL-CH1
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/33—Fusion polypeptide fusions for targeting to specific cell types, e.g. tissue specific targeting, targeting of a bacterial subspecies
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201361793153P | 2013-03-15 | 2013-03-15 | |
PCT/US2014/028731 WO2014144357A1 (en) | 2013-03-15 | 2014-03-14 | Tetravalent bispecific antibodies |
Publications (1)
Publication Number | Publication Date |
---|---|
HK1217958A1 true HK1217958A1 (zh) | 2017-01-27 |
Family
ID=50693997
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
HK16105955.4A HK1217958A1 (zh) | 2013-03-15 | 2016-05-25 | 四價雙特異性抗體 |
Country Status (12)
Country | Link |
---|---|
US (1) | US20160009824A1 (zh) |
EP (1) | EP2970485A1 (zh) |
JP (1) | JP2016514676A (zh) |
KR (1) | KR20150130349A (zh) |
CN (1) | CN105189557A (zh) |
AU (1) | AU2014227638A1 (zh) |
BR (1) | BR112015021921A2 (zh) |
CA (1) | CA2903056A1 (zh) |
HK (1) | HK1217958A1 (zh) |
MX (1) | MX2015012059A (zh) |
RU (1) | RU2015144098A (zh) |
WO (1) | WO2014144357A1 (zh) |
Families Citing this family (59)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU2010234031B2 (en) | 2009-04-07 | 2015-10-01 | Roche Glycart Ag | Trivalent, bispecific antibodies |
US9676845B2 (en) | 2009-06-16 | 2017-06-13 | Hoffmann-La Roche, Inc. | Bispecific antigen binding proteins |
SG179196A1 (en) | 2009-09-16 | 2012-04-27 | Genentech Inc | Coiled coil and/or tether containing protein complexes and uses thereof |
AR080793A1 (es) | 2010-03-26 | 2012-05-09 | Roche Glycart Ag | Anticuerpos biespecificos |
WO2012025530A1 (en) | 2010-08-24 | 2012-03-01 | F. Hoffmann-La Roche Ag | Bispecific antibodies comprising a disulfide stabilized - fv fragment |
EP2681240B1 (en) | 2011-02-28 | 2017-08-16 | F. Hoffmann-La Roche AG | Monovalent antigen binding proteins |
BR112013019975A2 (pt) | 2011-02-28 | 2017-08-01 | Hoffmann La Roche | proteínas de ligação de antígeno, composição farmacêutica, uso de uma proteína de ligação de antígeno, método para o tratamento de um paciente e método para a preparação de uma proteína de ligação de antígeno, ácido nucleico, vetor e célula hospedeira" |
WO2015052230A1 (en) | 2013-10-11 | 2015-04-16 | F. Hoffmann-La Roche Ag | Multispecific domain exchanged common variable light chain antibodies |
RU2769133C2 (ru) | 2013-12-30 | 2022-03-28 | Эпимаб Биотерапьютикс Инк. | Иммуноглобулин с тандемным расположением fab-фрагментов и его применение |
US20150307620A1 (en) * | 2014-04-16 | 2015-10-29 | University Of Connecticut | Linked immunotherapeutic agonists that costimulate multiple pathways |
DK3180363T3 (da) | 2014-08-15 | 2019-11-04 | Merck Patent Gmbh | Sirp-alpha-immunoglobulin fusionsproteiner |
CA2967595A1 (en) | 2014-11-12 | 2016-05-19 | Siamab Therapeutics, Inc. | Glycan-interacting compounds and methods of use |
US9879087B2 (en) | 2014-11-12 | 2018-01-30 | Siamab Therapeutics, Inc. | Glycan-interacting compounds and methods of use |
SG11201704056XA (en) | 2014-11-20 | 2017-06-29 | Hoffmann La Roche | Combination therapy of t cell activating bispecific antigen binding molecules cd3 abd folate receptor 1 (folr1) and pd-1 axis binding antagonists |
WO2016079076A1 (en) * | 2014-11-20 | 2016-05-26 | F. Hoffmann-La Roche Ag | T cell activating bispecific antigen binding molecules agiant folr1 and cd3 |
PL3227332T3 (pl) * | 2014-12-03 | 2020-06-15 | F. Hoffmann-La Roche Ag | Wielospecyficzne przeciwciała |
CN113150165A (zh) * | 2014-12-22 | 2021-07-23 | 西雅图免疫公司 | 双特异性四价抗体及其制造和使用方法 |
WO2017009419A1 (en) * | 2015-07-16 | 2017-01-19 | Ares Life Sciences S.A. | Bispecific antibody-like molecules having bivalency vis-à-vis each antigen |
MX2018003183A (es) * | 2015-09-15 | 2018-08-23 | Amgen Inc | Proteinas de enlace de antigeno biespecifico y tetraespecifico tetravalentes y usos de las mismas. |
JP7074665B2 (ja) * | 2015-10-07 | 2022-05-24 | エフ・ホフマン-ラ・ロシュ・アクチェンゲゼルシャフト | 共刺激tnf受容体に対する四価の二重特異性抗体発明の分野 |
KR20180088381A (ko) | 2015-11-12 | 2018-08-03 | 시아맙 쎄라퓨틱스, 인코포레이티드 | 글리칸-상호작용 화합물 및 사용방법 |
KR20180083895A (ko) * | 2015-12-11 | 2018-07-23 | 더 보드 어브 트러스티스 어브 더 리랜드 스탠포드 주니어 유니버시티 | Cd47 및 egfr의 이중 표적화를 이용한 암의 치료 |
CR20180365A (es) | 2015-12-16 | 2018-09-28 | Amgen Inc | PROTEÍNAS DE UNIÓN AL ANTÍGENO BISPECÍFICO DE ANTI-TL1A/ANTI-TNF-a Y SUS USOS |
SG11201805422WA (en) * | 2016-01-11 | 2018-07-30 | Inhibrx Inc | Multivalent and multispecific ox40-binding fusion proteins |
MX2018008934A (es) | 2016-01-22 | 2019-03-28 | Janssen Biotech Inc | Anticuerpos anti-ror1, anticuerpos biespecíficos ror1 x cd3 y métodos para su uso. |
CU24613B1 (es) * | 2016-02-06 | 2022-07-08 | Epimab Biotherapeutics Inc | Proteínas de unión a inmunoglobulinas fabs en tandem (fit-ig) biespecíficas que se unen a cmet y egfr |
CN107459579B (zh) * | 2016-06-01 | 2021-09-24 | 泰州迈博太科药业有限公司 | 一种靶向egfr和cd47双特异性融合蛋白、制备方法及应用 |
WO2018014068A1 (en) * | 2016-07-19 | 2018-01-25 | Teva Pharmaceuticals Australia Pty Ltd | Attenuated type i ifn cd47 combination therapy |
JP7241677B2 (ja) * | 2016-07-19 | 2023-03-17 | テバ・ファーマシューティカルズ・オーストラリア・ピーティワイ・リミテッド | 抗cd47併用療法 |
EP3541847A4 (en) | 2016-11-17 | 2020-07-08 | Seattle Genetics, Inc. | COMPOUNDS INTERACTING WITH GLYCANE AND METHODS OF USE |
KR101961871B1 (ko) * | 2017-02-20 | 2019-07-17 | 주식회사 와이바이오로직스 | 신규 다중특이적 결합 단백질 |
MA47812A (fr) | 2017-03-03 | 2021-04-14 | Seagen Inc | Composés interagissant avec le glycane et méthodes d'utilisation |
NZ756132A (en) * | 2017-03-10 | 2022-02-25 | Hoffmann La Roche | Method for producing multispecific antibodies |
CN108623689B (zh) * | 2017-03-15 | 2020-10-16 | 宜明昂科生物医药技术(上海)有限公司 | 新型重组双功能融合蛋白及其制备方法和用途 |
CN109957026A (zh) * | 2017-12-22 | 2019-07-02 | 成都恩沐生物科技有限公司 | 共价多特异性抗体 |
JP7288913B2 (ja) * | 2018-03-14 | 2023-06-08 | アフィメッド ゲゼルシャフト ミット ベシュレンクテル ハフツンク | 二重特異性egfr/cd16抗原結合タンパク質 |
US10654944B2 (en) | 2018-04-10 | 2020-05-19 | Y-Biologics Inc. | Cell engaging binding molecules |
CR20200549A (es) * | 2018-04-13 | 2021-03-18 | Affimed Gmbh | Constructos de fusión de anticuerpos que se acoplan a células nk |
WO2020036867A1 (en) | 2018-08-13 | 2020-02-20 | Inhibrx, Inc. | Ox40-binding polypeptides and uses thereof |
CN109824780A (zh) * | 2018-10-19 | 2019-05-31 | 包骏 | 一种用于研发药物的双功能融合蛋白平台 |
CA3118312A1 (en) * | 2018-10-29 | 2020-05-07 | Tigatx, Inc. | Compositions and methods comprising iga antibody constructs |
CN113490690A (zh) * | 2018-12-29 | 2021-10-08 | 南通壹宸生物医药科技有限公司 | 异源二聚体融合蛋白 |
JP2022525238A (ja) | 2019-04-01 | 2022-05-11 | インメタス セラピューティクス, インコーポレイテッド | 腫瘍微小環境および免疫チェックポイントタンパク質を標的とする二重特異性結合分子 |
TW202045550A (zh) * | 2019-04-05 | 2020-12-16 | 美商西建公司 | 腫瘤選擇性結合cd47之抗體之工程 |
EP3966227A1 (en) | 2019-05-07 | 2022-03-16 | Voyager Therapeutics, Inc. | Compositions and methods for the vectored augmentation of protein destruction, expression and/or regulation |
US20220267437A1 (en) * | 2019-07-29 | 2022-08-25 | Fred Hutchinson Cancer Research Center | Methods and compositions for inducing notch signaling in tumor microenvironments |
US20230374130A1 (en) | 2019-07-30 | 2023-11-23 | Qlsf Biotherapeutics, Inc. | Bispecific anti lrrc15 and cd3epsilon antibodies |
EP4010371A1 (en) | 2019-08-08 | 2022-06-15 | Regeneron Pharmaceuticals, Inc. | Novel antigen binding molecule formats |
US10994021B1 (en) * | 2020-04-11 | 2021-05-04 | Bliss Biopharmaceutical (Hangzhou) Co., Ltd. | Tetravalent antibody-drug conjugates and use thereof |
CN113563473A (zh) * | 2020-04-29 | 2021-10-29 | 三生国健药业(上海)股份有限公司 | 四价双特异性抗体、其制备方法和用途 |
JP2023545983A (ja) * | 2020-10-07 | 2023-11-01 | セルジーン コーポレイション | リンパ系悪性腫瘍状態の二重特異性抗体治療 |
WO2023023055A1 (en) | 2021-08-16 | 2023-02-23 | Renagade Therapeutics Management Inc. | Compositions and methods for optimizing tropism of delivery systems for rna |
WO2023044333A1 (en) | 2021-09-14 | 2023-03-23 | Renagade Therapeutics Management Inc. | Cyclic lipids and methods of use thereof |
WO2023044343A1 (en) | 2021-09-14 | 2023-03-23 | Renagade Therapeutics Management Inc. | Acyclic lipids and methods of use thereof |
AR127273A1 (es) * | 2021-10-09 | 2024-01-03 | Hutchmed Ltd | Anticuerpos biespecíficos que se unen específicamente a cd47 y her2 y usos de los mismos |
WO2023072159A1 (en) * | 2021-10-27 | 2023-05-04 | Virtuoso Binco, Inc. | Multispecific antibodies for treating cd47-associated diseases |
WO2023122752A1 (en) | 2021-12-23 | 2023-06-29 | Renagade Therapeutics Management Inc. | Constrained lipids and methods of use thereof |
WO2023196931A1 (en) | 2022-04-07 | 2023-10-12 | Renagade Therapeutics Management Inc. | Cyclic lipids and lipid nanoparticles (lnp) for the delivery of nucleic acids or peptides for use in vaccinating against infectious agents |
WO2023204290A1 (ja) * | 2022-04-21 | 2023-10-26 | 愛知県 | 多重特異性ナノ粒子 |
Family Cites Families (14)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP2364997A3 (en) | 1999-01-15 | 2012-07-04 | Genentech, Inc. | Polypeptide variants with altered effector function |
KR100900176B1 (ko) | 2001-03-07 | 2009-06-02 | 메르크 파텐트 게엠베하 | 하이브리드 이소타입 항체 부분구조를 포함하는 단백질을위한 발현 기술 |
JP2010535032A (ja) * | 2007-07-31 | 2010-11-18 | メディミューン,エルエルシー | 多重特異性エピトープ結合性タンパク質およびその用途 |
US9266967B2 (en) * | 2007-12-21 | 2016-02-23 | Hoffmann-La Roche, Inc. | Bivalent, bispecific antibodies |
JP5522405B2 (ja) | 2008-04-25 | 2014-06-18 | 協和発酵キリン株式会社 | 安定な多価抗体 |
AU2010234031B2 (en) * | 2009-04-07 | 2015-10-01 | Roche Glycart Ag | Trivalent, bispecific antibodies |
BRPI1007602A2 (pt) * | 2009-05-27 | 2016-02-16 | Hoffmann La Roche | "anticorpo tri ou tetraespecífico, método para preparação de um anticorpo triespecífico ou tetraespecífico, célula hospedeira, composição, composição farmacêutica e método para o tratamento de um paciente com necessidade de terapia" |
US9676845B2 (en) * | 2009-06-16 | 2017-06-13 | Hoffmann-La Roche, Inc. | Bispecific antigen binding proteins |
US8703132B2 (en) * | 2009-06-18 | 2014-04-22 | Hoffmann-La Roche, Inc. | Bispecific, tetravalent antigen binding proteins |
PT2748202T (pt) * | 2011-08-23 | 2018-10-08 | Roche Glycart Ag | Moléculas de ligação ao antigénio biespecíficas |
US20150183877A1 (en) * | 2012-07-18 | 2015-07-02 | Eli Lilly And Company | Multi-Specific IgG-(Fab)2 Constructs Containing T-Cell Receptor Constant Domains |
UA118028C2 (uk) * | 2013-04-03 | 2018-11-12 | Рош Глікарт Аг | Біспецифічне антитіло, специфічне щодо fap і dr5, антитіло, специфічне щодо dr5, і спосіб їх застосування |
DK3180363T3 (da) * | 2014-08-15 | 2019-11-04 | Merck Patent Gmbh | Sirp-alpha-immunoglobulin fusionsproteiner |
EP3150636A1 (en) * | 2015-10-02 | 2017-04-05 | F. Hoffmann-La Roche AG | Tetravalent multispecific antibodies |
-
2014
- 2014-03-14 EP EP14723568.3A patent/EP2970485A1/en not_active Withdrawn
- 2014-03-14 CN CN201480016032.9A patent/CN105189557A/zh active Pending
- 2014-03-14 AU AU2014227638A patent/AU2014227638A1/en not_active Abandoned
- 2014-03-14 KR KR1020157027312A patent/KR20150130349A/ko not_active Application Discontinuation
- 2014-03-14 CA CA2903056A patent/CA2903056A1/en not_active Abandoned
- 2014-03-14 JP JP2016502882A patent/JP2016514676A/ja active Pending
- 2014-03-14 US US14/777,152 patent/US20160009824A1/en not_active Abandoned
- 2014-03-14 RU RU2015144098A patent/RU2015144098A/ru not_active Application Discontinuation
- 2014-03-14 BR BR112015021921A patent/BR112015021921A2/pt active Search and Examination
- 2014-03-14 WO PCT/US2014/028731 patent/WO2014144357A1/en active Application Filing
- 2014-03-14 MX MX2015012059A patent/MX2015012059A/es unknown
-
2016
- 2016-05-25 HK HK16105955.4A patent/HK1217958A1/zh unknown
Also Published As
Publication number | Publication date |
---|---|
AU2014227638A1 (en) | 2015-09-17 |
CN105189557A (zh) | 2015-12-23 |
CA2903056A1 (en) | 2014-09-18 |
MX2015012059A (es) | 2016-01-12 |
JP2016514676A (ja) | 2016-05-23 |
BR112015021921A2 (pt) | 2017-08-29 |
RU2015144098A (ru) | 2017-04-21 |
EP2970485A1 (en) | 2016-01-20 |
US20160009824A1 (en) | 2016-01-14 |
KR20150130349A (ko) | 2015-11-23 |
WO2014144357A1 (en) | 2014-09-18 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
IL269528A (en) | Anti- FCRH5 antibodies | |
HK1217958A1 (zh) | 四價雙特異性抗體 | |
HK1217023A1 (zh) | 新型抗體 | |
ZA201506568B (en) | Anti-tnf-anti-il-17 bispecific antibodies | |
EP2970505A4 (en) | SPECIFIC ANTIBODIES AND USES THEREOF | |
GB201322583D0 (en) | Antibodies | |
HK1220142A1 (zh) | 抗體 | |
GB201308658D0 (en) | Antibodies | |
GB201315486D0 (en) | Antibodies | |
IL245488B (en) | Anti- ccl17 antibodies | |
GB201312226D0 (en) | Improved antibodies | |
GB201318283D0 (en) | Antibodies |